- Home
- UUU vs CMMB Comparison
UUU vs CMMB Comparison
Compare UUU & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UUU
- CMMB
- Stock Information
- Founded
- UUU 1969
- CMMB 2004
- Country
- UUU United States
- CMMB Israel
- Employees
- UUU N/A
- CMMB N/A
- Industry
- UUU Electronic Components
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- UUU Technology
- CMMB Health Care
- Exchange
- UUU Nasdaq
- CMMB Nasdaq
- Market Cap
- UUU 12.6M
- CMMB 13.8M
- IPO Year
- UUU N/A
- CMMB N/A
- Fundamental
- Price
- UUU $3.97
- CMMB $2.43
- Analyst Decision
- UUU
- CMMB Strong Buy
- Analyst Count
- UUU 0
- CMMB 2
- Target Price
- UUU N/A
- CMMB $26.50
- AVG Volume (30 Days)
- UUU 46.2K
- CMMB 81.1K
- Earning Date
- UUU 11-19-2025
- CMMB 11-20-2025
- Dividend Yield
- UUU 25.77%
- CMMB N/A
- EPS Growth
- UUU N/A
- CMMB N/A
- EPS
- UUU 0.49
- CMMB N/A
- Revenue
- UUU $16,346,015.00
- CMMB N/A
- Revenue This Year
- UUU N/A
- CMMB N/A
- Revenue Next Year
- UUU N/A
- CMMB N/A
- P/E Ratio
- UUU $7.77
- CMMB N/A
- Revenue Growth
- UUU N/A
- CMMB N/A
- 52 Week Low
- UUU $1.65
- CMMB $2.39
- 52 Week High
- UUU $8.27
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- UUU 39.72
- CMMB 37.71
- Support Level
- UUU $3.63
- CMMB $2.48
- Resistance Level
- UUU $4.55
- CMMB $2.85
- Average True Range (ATR)
- UUU 0.39
- CMMB 0.22
- MACD
- UUU -0.06
- CMMB -0.02
- Stochastic Oscillator
- UUU 22.67
- CMMB 4.62
About UUU Universal Security Instruments Inc.
Universal Safety Products Inc is a U.S.-based importer and distributor of home safety devices such as ventilation fans and ground fault circuit interrupters.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.